Middle East Healthcare Company SJSC 4009.SR · SAR

Health Care · Tadawul · 🇸🇦 Saudi Arabia

Compare

26.10

+3.41%

Close of 9 Nov 2026, in SAR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in SAR, from our data supplier.

FY2025

Revenue

SAR 3.10bn

FY2016FY2025

Net income

SAR 301.9m

FY2016FY2025

Free cash flow

−SAR 99.8m

FY2016FY2025

Shareholders' equity

SAR 1.87bn

FY2016FY2025

Income statement

Fiscal years

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Revenue	SAR 3.10bn	SAR 2.88bn	SAR 2.65bn	SAR 2.15bn	SAR 1.87bn	SAR 1.77bn	SAR 1.50bn	SAR 1.39bn	SAR 1.63bn	SAR 1.62bn
Gross profit	SAR 1.16bn	SAR 1.11bn	SAR 1.00bn	SAR 680.0m	SAR 608.2m	SAR 600.0m	SAR 472.9m	SAR 500.7m	SAR 764.9m	SAR 827.7m
Operating income	SAR 390.6m	SAR 440.9m	SAR 342.5m	SAR 213.5m	SAR 54.2m	SAR 165.6m	SAR 130.3m	SAR 162.7m	SAR 311.2m	SAR 370.1m
Net income	SAR 301.9m	SAR 282.0m	SAR 180.2m	SAR 75.2m	SAR 11.7m	SAR 82.0m	SAR 97.6m	SAR 172.2m	SAR 300.1m	SAR 361.9m
Diluted earnings per share	4.17	3.06	1.96	0.82	0.11	0.89	1.06	1.88	3.26	3.93

Balance sheet

At each fiscal year end

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Total assets	SAR 5.47bn	SAR 5.13bn	SAR 5.17bn	SAR 4.50bn	SAR 3.97bn	SAR 3.96bn	SAR 3.31bn	SAR 2.73bn	SAR 2.68bn	SAR 2.51bn
Cash and short-term investments	SAR 26.3m	SAR 52.3m	SAR 44.4m	SAR 15.6m	SAR 28.1m	SAR 16.9m	SAR 53.9m	SAR 44.2m	SAR 111.1m	SAR 155.1m
Total liabilities	SAR 3.54bn	SAR 3.45bn	SAR 3.61bn	SAR 3.09bn	SAR 2.68bn	SAR 2.32bn	SAR 1.74bn	SAR 2.73bn	SAR 923.6m	SAR 910.1m
Debt	SAR 2.43bn	SAR 2.47bn	SAR 2.49bn	SAR 2.24bn	SAR 1.97bn	SAR 1.55bn	SAR 1.03bn	SAR 616.3m	SAR 303.9m	SAR 315.2m
Shareholders' equity	SAR 1.87bn	SAR 1.63bn	SAR 1.52bn	SAR 1.36bn	SAR 1.26bn	SAR 1.59bn	SAR 1.52bn	SAR 1.45bn	SAR 1.70bn	SAR 1.54bn
Shares outstanding	72m	92m	92m	92m	108m	92m	92m	92m	92m	92m

Cash flow

Fiscal years

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Cash from operations	SAR 355.4m	SAR 766.0m	SAR 191.1m	SAR 76.0m	SAR 76.6m	−SAR 263.4m	SAR 98.6m	SAR 161.4m	SAR 340.6m	SAR 257.3m
Capital spending	−SAR 455.2m	−SAR 479.3m	−SAR 232.4m	−SAR 249.5m	−SAR 417.5m	−SAR 294.3m	−SAR 472.1m	−SAR 356.7m	−SAR 234.8m	−SAR 140.2m
Free cash flow	−SAR 99.8m	SAR 286.7m	−SAR 41.3m	−SAR 173.5m	−SAR 340.9m	−SAR 557.7m	−SAR 373.5m	−SAR 195.4m	SAR 105.8m	SAR 117.1m
Dividends paid	−SAR 46.0m	—	—	—	—	—	—	−SAR 184.1m	−SAR 184.1m	−SAR 184.1m

Latest quarters

By quarter end

	Jun 2026	Mar 2026	Dec 2025	Sept 2025	Jun 2025	Mar 2025	Dec 2024	Sept 2024
Revenue	SAR 845.5m	SAR 765.2m	SAR 808.8m	SAR 769.0m	SAR 791.1m	SAR 733.7m	SAR 748.9m	SAR 732.1m
Gross profit	SAR 266.5m	SAR 254.3m	SAR 284.4m	SAR 283.9m	SAR 308.0m	SAR 283.7m	SAR 282.1m	SAR 292.9m
Operating income	SAR 88.4m	SAR 74.5m	SAR 87.0m	SAR 87.4m	SAR 121.1m	SAR 154.8m	SAR 154.2m	SAR 115.9m
Net income	SAR 34.3m	SAR 25.7m	SAR 37.8m	SAR 40.3m	SAR 63.7m	SAR 160.1m	SAR 107.1m	SAR 61.7m
Diluted earnings per share	0.37	0.28	0.52	0.56	0.88	2.21	1.16	0.67
Cash from operations	SAR 74.0m	SAR 281.0m	−SAR 56.0m	SAR 351.0m	−SAR 103.0m	SAR 289.0m	SAR 128.0m	SAR 397.0m
Capital spending	—	−SAR 153.0m	−SAR 94.0m	−SAR 199.0m	−SAR 105.0m	−SAR 55.0m	−SAR 74.0m	−SAR 268.0m
Free cash flow	—	SAR 128.0m	−SAR 150.0m	SAR 152.0m	−SAR 208.0m	SAR 234.0m	SAR 54.0m	SAR 129.0m
Total assets	SAR 5.16bn	SAR 5.47bn	SAR 5.47bn	SAR 5.28bn	SAR 5.32bn	SAR 5.22bn	SAR 5.13bn	SAR 5.16bn
Cash and short-term investments	—	—	SAR 26.3m	SAR 70.0m	SAR 31.9m	SAR 282.1m	SAR 52.3m	SAR 49.9m
Debt	SAR 1.58bn	SAR 1.56bn	SAR 2.43bn	SAR 2.32bn	SAR 2.34bn	SAR 2.32bn	SAR 2.39bn	SAR 2.41bn
Shareholders' equity	SAR 1.54bn	SAR 1.90bn	SAR 1.87bn	SAR 1.84bn	SAR 1.80bn	SAR 1.79bn	SAR 1.63bn	SAR 1.70bn

Financial ratios

Data as of 23 Oct 2026

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	37.4%	38.6%	37.8%	31.6%	32.5%	33.9%
Operating margin	12.6%	18.4%	13.0%	6.5%	2.9%	6.6%
Net margin	9.7%	9.8%	6.8%	3.5%	0.6%	4.6%
Return on equity	16.1%	17.3%	11.9%	5.5%	0.9%	5.2%
Return on assets	5.5%	5.5%	3.5%	1.7%	0.3%	2.1%
Free cash flow yield	46.8%	56.6%	19.2%	14.8%	19.2%	1.4%
Revenue growth	7.6%	8.7%	23.3%	14.9%	5.7%	18.4%
Earnings growth	7.0%	56.5%	139.7%	540.8%	-85.7%	-16.0%
Current ratio	1.55x	1.72x	1.29x	1.20x	1.15x	1.56x
Debt to equity	1.30x	1.47x	1.61x	1.60x	1.54x	0.96x
Equity ratio	34.3%	31.7%	29.4%	30.3%	31.7%	40.2%
Interest coverage	1.93x	2.36x	2.15x	2.13x	1.31x	3.75x
Buybacks as a share of market value	21.3%	0.0%	0.0%	14.5%	-16.9%	0.3%

Growth per year

Compound annual rate

	3 years	5 years	10 years
Revenue	13.0%	11.9%	7.3%
Operating income	22.3%	18.7%	-0.1%
Net income	58.9%	29.8%	-2.5%

Average margins

Over each period

	1 year	3 years	5 years	10 years
Gross margin	38.0%	36.7%	35.8%	38.6%
Operating margin	13.9%	12.9%	11.1%	13.5%
Net margin	9.8%	7.8%	6.5%	10.2%

Valuation history

At each fiscal year end

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Price to earnings	7.8	22.4	45.1	31.2	290.3	39.4	28.1	17.3	16.6	18.7
Price to sales	0.8	2.2	3.1	1.1	1.8	1.8	1.8	2.1	3.0	4.2

Dividends and splits

Per share, in the currency the company pays

Paid for 1 years. Last went ex-dividend on 9 Jul 2025.

	FY2025	FY2018	FY2017	FY2016
Paid in the year	0.50	2.00	2.00	2.00

Sources and methodology

Data on this tab: Our data supplier
Chart on the Overview: TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.

Asset classes

Countries / Regions

Market tools

News & insights

Middle East Healthcare Company SJSC 4009.SR · SAR

Search any instrument

At a glance

Income statement

Balance sheet

Cash flow

Latest quarters

Financial ratios

Growth per year

Average margins

Valuation history

Dividends and splits

Sources and methodology